Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

NIH has long overseen extraordinary achievements in biomedical knowledge that have been catalyzed by the NIH's traditional peer-review process ... of the "bugto-drug" timeline will not occur ...

Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...

A decline in R&D investment in neglected tropical diseases threatens progress toward critical targets. For over 20 years, one ...

In this month’s wind-driven wildfires in Southern California, evacuation alerts for some neighborhoods came long after homes ...

The Trump administration has pressed the pause button on the U.S.’s vital biomedical research engine, the National Institutes for Health. Grant reviews, travel and hiring appear to be on indefinite ...

Kash Patel dodges questions on Jan 6 and 2020 election during FBI confirmation hearing - RFK Jr, Tulsi Gabbard and Kash Patel ...

Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...

Elizabeth Rose Struhs died on January 7, 2022 while lying on a mattress on the floor of her family’s Toowoomba home, west of ...

The Trump administration has pressed the pause button on the U.S.’s vital biomedical research engine, the National Institutes ...

The Massachusetts Legislature passed legislation that will close loopholes in the health care market regulatory process exposed by the collapse of Steward Health Care, increase financial transparency ...

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.